Active substances
Atovaquone + Proguanil
- SFDA 2
- US FDA 4
- Health Canada 6
- US price lines 2
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| MALARONE | 250,100 mg,mg | Film-coated tablet · Oral use | 12 Blister | SAR 124.05 | NCE · Prescription | GLAXOWELLCOME | Valid |
| MALAUST | 250,100 mg,mg | Film-coated tablet · Oral use | 12 Blister | SAR 44.25 | Generic · Prescription | Glenmark Pharmaceuticals Limited | Valid |
Indications — CHI Daman Drug Formulary
MALARIA-PREVENTION AND CHEMOPROPHYLAXIS; RENAL TRANSPLANT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MALARONE | 250MG;100MG | tablet · oral | GLAXOSMITHKLINE | Prescription | 14 Jul 2000 |
| MALARONE PEDIATRIC | 62.5MG;25MG | tablet · oral | GLAXOSMITHKLINE | Prescription | 14 Jul 2000 |
| ATOVAQUONE AND PROGUANIL HYDROCHLORIDE | 250MG;100MG; 62.5MG;25MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 12 Jan 2011 |
| ATOVAQUONE AND PROGUANIL HYDROCHLORIDE | 62.5MG;25MG; 250MG;100MG | tablet · oral | MYLAN | Prescription | 27 May 2014 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ATOVAQUONE AND PROGUANIL HYDROCHLORIDE TABLETS | 02466783 | 250 MG; 100 MG | TABLET · ORAL | GLENMARK PHARMACEUTICALS CANADA INC. |
| ATOVAQUONE PROGUANIL | 02421429 | 100 MG; 250 MG | TABLET · ORAL | SANIS HEALTH INC |
| MALARONE | 02238151 | 250 MG; 100 MG | TABLET · ORAL | GLAXOSMITHKLINE INC |
| MALARONE PEDIATRIC | 02264935 | 62.5 MG; 25.0 MG | TABLET · ORAL | GLAXOSMITHKLINE INC |
| MYLAN-ATOVAQUONE/PROGUANIL | 02402165 | 100 MG; 250 MG | TABLET · ORAL | MYLAN PHARMACEUTICALS ULC |
| TEVA-ATOVAQUONE PROGUANIL | 02380927 | 250 MG; 100 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ATOVAQUONE-PROGUANIL 250-100 MG TABLET | $1.48584 | per EA | 23 Sep 2026 |
| US NADAC | ATOVAQUONE-PROGUANIL 62.5-25 | $0.92749 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Proguanil 100mg / Atovaquone 250mg tablets | £25.21 | 12 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Proguanil 25mg / Atovaquone 62.5mg tablets | £6.26 | 12 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.